Peak6 LLC Makes New $707,000 Investment in Cellebrite DI Ltd. (NASDAQ:CLBT)

PEAK6 LLC purchased a new position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 32,099 shares of the company's stock, valued at approximately $707,000.

Other large investors have also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. raised its holdings in Cellebrite DI by 21.3% during the third quarter. JPMorgan Chase & Co. now owns 427,655 shares of the company's stock worth $7,202,000 after purchasing an additional 75,092 shares during the last quarter. Harbor Capital Advisors Inc. increased its stake in Cellebrite DI by 65.4% in the fourth quarter. Harbor Capital Advisors Inc. now owns 157,671 shares of the company's stock valued at $3,473,000 after purchasing an additional 62,320 shares during the last quarter. Raymond James Financial Inc. purchased a new position in shares of Cellebrite DI during the 4th quarter worth about $9,995,000. State Street Corp boosted its holdings in shares of Cellebrite DI by 7.3% in the 3rd quarter. State Street Corp now owns 443,700 shares of the company's stock valued at $7,472,000 after purchasing an additional 30,052 shares during the last quarter. Finally, New York State Common Retirement Fund raised its position in shares of Cellebrite DI by 2.6% in the 4th quarter. New York State Common Retirement Fund now owns 189,599 shares of the company's stock worth $4,177,000 after buying an additional 4,838 shares during the period. 45.88% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

CLBT has been the topic of a number of research reports. Lake Street Capital raised their price objective on Cellebrite DI from $17.00 to $26.00 and gave the stock a "buy" rating in a report on Friday, February 14th. JPMorgan Chase & Co. lifted their price target on shares of Cellebrite DI from $24.00 to $28.00 and gave the company an "overweight" rating in a research report on Tuesday, February 11th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $28.00 target price on shares of Cellebrite DI in a research note on Wednesday, April 2nd. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $23.43.

Cellebrite DI Stock Up 0.4 %

Shares of Cellebrite DI stock traded up $0.08 during trading hours on Friday, hitting $19.64. 468,650 shares of the company's stock traded hands, compared to its average volume of 1,411,353. Cellebrite DI Ltd. has a twelve month low of $10.25 and a twelve month high of $26.30. The company has a market cap of $4.70 billion, a PE ratio of -14.13, a PEG ratio of 4.27 and a beta of 1.44. The stock has a 50 day simple moving average of $18.73 and a 200-day simple moving average of $20.11.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last released its earnings results on Thursday, February 13th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.03). Cellebrite DI had a positive return on equity of 58.70% and a negative net margin of 70.54%. As a group, equities research analysts predict that Cellebrite DI Ltd. will post 0.3 EPS for the current year.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.